Finding genetic weak spots in lung cancer

Uncovering Oncogenotype-specific Vulnerabilities in Lung cancer

NIH-funded research Yale University · NIH-11310212

Looks for nutrient and metabolism weak spots tied to specific gene changes in non-small cell lung cancer, especially tumors with KRAS or KRAS+LKB1 mutations.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionYale University NIH-funded
Lab location1 site (New Haven, United States)
Project IDNIH-11310212 on NIH RePORTER

What this research studies

This project compares the metabolism of human non-small cell lung tumors that carry KRAS mutations with those that carry both KRAS and LKB1 changes to find vulnerabilities. Researchers analyze surgically removed tumor tissue using metabolite profiling and genomic methods to see which metabolic pathways the tumors depend on. They compare lung results with findings from other organs to understand how tissue type changes metabolic needs. The goal is to find metabolic pathways that could be targeted with drugs for patients whose tumors show those specific genetic patterns.

Who could benefit from this research

Good fit: Ideal candidates are people with non-small cell lung cancer whose tumors have KRAS mutations or KRAS plus LKB1 co-mutations, especially if they are having surgery or can donate tumor tissue.

Not a fit: Patients without NSCLC or without KRAS/KL tumor mutations are unlikely to see a direct benefit from this specific project.

Why it matters

Potential benefit: If successful, this work could point to new treatment targets that exploit metabolic weaknesses in lung tumors with particular gene mutations.

How similar studies have performed: Related preclinical studies have found metabolic weak spots in some cancers, but applying oncogenotype-specific metabolic targeting to KRAS/LKB1 lung cancer is comparatively new.

Where this research is happening

New Haven, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.